Home › Trials › NCT07294547
Clinical trial Recruiting at 1 site Interventional Ages 3 and up

Valacyclovir versus valganciclovir to prevent CMV and EBV after kidney transplant

Official title: Non-Inferiority Assessment of Valacyclovir Versus Valganciclovir as Prophylaxis Against CMV and EBV Viremia in Kidney Transplant Recipients: A Single-Center Prospective Randomized Pilot Study.

Run by National Taiwan University Hospital · NCT07294547 · Data updated 2026-11-12

This test checks whether valacyclovir works as well as valganciclovir to prevent CMV and EBV in people who recently had a kidney transplant.

Quick facts

Study typeInterventional
Ages3 Years and up
SexAll
Enrollment80 (estimated)
SponsorNational Taiwan University Hospital
Academic / other
Locations1 site (Taipei)
StatusRecruiting
StartedNovember 27, 2025
Main results expectedDecember 2029
Study endsDecember 2030
Registry record updatedDecember 19, 2025
Trial IDNCT07294547 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are kidney transplant recipients age 3 or older within two weeks of transplantation who have no detectable CMV or EBV viremia at screening and can provide consent and attend follow-up at the study site.

Probably not a fit

Patients with active CMV or EBV viremia at screening, pregnant patients, those with severe comorbidities that preclude safe participation, or those allergic to both medications are unlikely to benefit from joining this protocol.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This single-center, prospective, randomized non-inferiority pilot compares valacyclovir and valganciclovir as antiviral prophylaxis in kidney transplant recipients. Eligible participants (age ≥3) are enrolled within two weeks of transplantation if they have no detectable CMV or EBV viremia and are randomized to receive one of the two antiviral regimens. Follow-up includes regular viral load surveillance for CMV and EBV and safety monitoring for hematologic and renal adverse effects. The study aims to compare the incidence of post-transplant CMV and EBV viremia and record tolerability and adverse events between the two drugs.

Why it matters

Potential benefit: If successful, this could provide a less toxic and lower-cost option for CMV/EBV prevention with reduced risk of bone marrow suppression.

How similar studies have gone: Some retrospective studies suggest valacyclovir may perform comparably to valganciclovir for CMV prophylaxis, but prospective randomized evidence is limited, so the approach is partly supported but not well established.

Who can join: the full rules

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Age at least 3 years of age
* Patients who are about to receive or just received kidney transplantation within the past 2 weeks before the date of screening.
* Will be receiving prophylactic antiviral therapy against CMV and/or EBV per discretion of transplant surgeon
* No active CMV or EBV viremia (as defined by detectable viral load PCR) at the time of screening.
* Ability and willingness of the patient (or parent/legal guardian for minors) to provide informed consent and comply with study procedures.

Exclusion Criteria:

* Severe co-morbidities that would preclude safe participation as judged by the transplant surgeon
* Pregnancy (valganciclovir is likely teratogenic)
* Known allergy to both valacyclovir and valganciclovir

Where it's running

  • National Taiwan University Hospital
    Taipei, Taiwan     Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov ↗ Find more trials like this →
Browse more
EBV Infection 7National Taiwan University Hospital 278
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.